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104 Poster Session IIpatients undergoing allogeneic hematopoietic stem cell transplanta-
tion (alloSCT) is unclear. We performed a retrospective matched-
control study of the outcomes of 31 patients with serological evi-
dence of HC at the time they underwent alloSCT for a variety of
hematological malignancies between 1998 and 2007 at the UTM-
DACC. For comparison, we identified 31 control patients with neg-
ative serology forHC,matched on age group, diagnosis, disease risk
(poor vs. good), intensity of conditioning regimen (reduced vs. mye-
loablative) and donor type (referred to as matched controls). To con-
firm the validity of the matching procedure we extended the
comparison to the 1800 seronegative patients (all controls) trans-
planted for the same diseases during the same period of time. Mul-
tivariate analysis took into account all variables used in our
matching procedure.
The median age of the HC patients was 49 (range 26–72); 15 had
AML/MDS, 6 CML/MPD, 6 non-Hodgkin lymphoma, 2 mye-
loma, 1 ALL and 1 Hodgkin lymphoma; 61% of had poor risk dis-
ease, 68% had related donors, and 68% received reduced intensity
conditioning. These characteristics were identical to those of the
matched control group. There were also no significant differences
in baseline liver function: immediately prior to starting condition-
ing, only 7 patients in the HC group and 5 patients in the matched
control group had an alanine transaminase (ALT) level greater than
the upper limit of normal (ULN), but all less than 3ULN (ranges
69–185 and 69–178 IU/L); only one patient in theHCgroup (versus
none in the matched control) had a total bilirubin level above the
ULN (1.2ULN).
Median follow-up was 34 (range 3–53), 27 (4–74) and 29 months
(1–108), respectively for HC, matched and all controls. Overall sur-
vival post-alloSCT was significantly inferior in the HC group, with
a median OS of 3 versus 18 and 20 months in the control groups.
The cumulative rate of disease progression and acute or chronic
GVHD was comparable, but NRM was significantly increased in
the HC group. Results were similar regardless of the control group
used, validating our matching algorithm. In summary, serological
evidence of HC virus infection at the time of alloSCT, even with
normal or minimally abnormal liver function tests, is associated
with worse survival after alloSCT, due to an increased rate of
non-relapse deaths.Patients with hepatitis C have worse overall survival and non-relapse
mortality than controls after SCT
Matched analysis Multivariate analysisOutcome
mHC (N 5 31) vs.
atched controls
(N 5 31), % HR (95% CI) PHC (N 5 31) vs.
all controls
(N 5 1800), % HR (95% CI) POS:3 mo 58 vs. 87 3.6 (1.2–11.0) 0.03 58 vs. 87 3.9 (2.2–6.8) \0.001
1 yr 29 vs. 56 2.4 (1.2–4.9) 0.01 29 vs. 56 3.1 (1.9–5.6) \0.001NRM:3 mo 29 vs. 13 2.5 (0.8–8.1) 0.1 29 vs. 10 3.6 (1.8–7.1) \0.001
1 yr 43 vs. 24 2.9 (1.1–7.7) 0.03 43 vs. 23 3.3 (1.9–5.6) \0.01HC: hepatitis C, OS: overall survival, NRM: non-relapse mortality,
HR: hazard ratio, CI: confidence interval.281
SERIAL VORICONAZOLE THERAPEUTIC DRUG MONITORING IN RECIPI-
ENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Trifilio, S.M.1, Yarnold, P.R.1, Pennick, G.2, Pi, J.C.1, Golf, M.1,
Fishman,M.1, Masino, K.1, Mehta, J.1. 1Northwestern University, Chi-
cago; 2University of Texas at San Antonio, San Antonio.
Voriconazole is effective for prophylaxis and therapy of invasive
fungal infections (IFI). It is metabolized by the CYP450 system
2C19, 2C9 and 3A4 isosenzymes. We have reported that significant
interpatient variability exists in plasma voriconazole concentrations
after allogeneic HSCT and that about 15% of patients have no de-
tectable voriconazole in the plasma despite adequate dose (Trifilio
et al. Cancer 2007;109:1532–1535). Low plasma levels have alsobeen associated with decreased survival in patients with aspergillosis
and increased breaktrough Candida glabrata infections (Trifilio et
al. Bone Marrow Transplant 2007;40:451–456). Treatment or pro-
phylaxis for IFIs after HSCT is prolonged, and changing conditions
are likely to alter voriconazole pharmacokinetics which may predis-
pose to treatment failure. We studied the relationship between the
first and second voriconazole levels in 29 allogeneic HSCT recipi-
ents whose first plasma voriconazole level was adequate (.2 mg/
mL). The first level was drawn 6 days after starting voriconazole
(usually day 16 post-HSCT), and the second level was drawn at
a variable time after the first (median 9 days; range 1–252 days).
The majority of patients received the drug at the dose of 200 mg
twice a day orally. The two levels were strongly correlated to
each-other (r 5 0.72; p\ 0.0001), but not to the interval between
the two (p\ 0.6) or weight (p\ 0.49). 10 patients had a level\2
mg/mL on the second measurement. Optimal discriminant analysis
revealed that all 11 patients with an initial voriconazole level #4.6
mg/mL had a second level that was\2 mg/mL (p\ 0.02). Neither
the interval between the two levels (p \ 0.15) or weight (p \
0.75) predicted whether a patient’s second voriconazole level was
\2 mg/mL. However, when the analysis was expanded to a total
of 43 patients in whom the first level was $1 mg/mL, 10 of whom
had a second level of\1 mg/mL, no factor could be found that could
reliably predict for a second level of\1 mg/mL. These data suggest
that serial plasma voriconazole levels can change in an unpredict-
able fashion over time after HSCT - sometimes decreasing to levels
that may place the patient at risk for breakthrough IFIs. Patients
who require prolonged voriconazole administration may benefit
from ongoing therapeutic drug monitoring and dose adjustment.282
EFFICIENT INDUCTION AND ISOLATION OF A PRIMARY CMV-SPECIFIC
CD81 T CELL RESPONSE FROM CMV SERONEGATIVE DONORS FOR
THE TREATMENT OF SERIOUS CMV-RELATED COMPLICATIONS IN
CMV SEROPOSITIVE PATIENTS TRANSPLANTEDWITH A CMV SERONEG-
ATIVE DONOR
Jedema, I., van de Meent, M., van der Heiden, P.L.J., Marijt, E.W.A.,
Meij, P., Willemze, R., Falkenburg, J.H.F. Leiden University Medical
Center, Leiden, Netherlands.
Cytomegalovirus (CMV) disease is a significant cause of morbid-
ity and mortality after allogeneic stem cell transplantation
(allo-SCT). Especially in CMV seropositive (CMV1) patients
transplanted with a CMV- donor, a high incidence of CMV related
mortality is seen. We recently demonstrated in a phase I/II clinical
study the feasibility of selecting CMV-specific CD81 memory T
cells from CMV1 donors using the interferon-gamma (IFNg) cap-
ture assay and CliniMACS isolation after peptide stimulation of the
CMV-specific donor T cells. We have illustrated the in-vivo poten-
tial of these T cells after adoptive transfer in 5 patients with persis-
tent CMV reactivation despite seropositivity of the donor, resulting
in clearance of the CMV load. However, no suitable method was
available for the induction of primary immune responses against
CMV for the treatment of persistent CMV reactivation in the
high risk group of patients transplanted with a CMV- donor. In
the current study we investigated the possibility to induce and iso-
late CMV-specific T cells from CMV- healthy donors by in-vitro
priming and selection. We used as responder cells CD45RO-
PBMC from HLA-A1, A2, A3, B7, or B8 positive CMV- donors
(n5 13). By CD45RO depletion we removed the majority of regu-
latory T cells capable of inhibiting the initiation of the response.
Naı¨ve donor T cells were cocultured in the presence of IL-7 and
IL-15 with mature monocyte-derived dendritic cells loaded with
a cocktail containing 1mg of each relevant CMV pp65, pp50, or
IE1 derived 9-mer peptide. At day 10, the responses were specifi-
cally restimulated with peptide loaded autologous PBMC. At day
20 CMV-specific CD81 T cells were detected by specific tetramer
or pentamer staining, and isolated by flowcytometric cell sorting or
magnetic bead isolation, or further enriched by another restimula-
tion, followed by isolation of CD137 or IFNg expressing T cells
at day 21. In 13/13 CMV- donors CMV specific T cells could be de-
tected at day 20 of the immune response in frequencies ranging
from 0.01–0.4%. Functional CMV-specific T cells against all 3 ma-
jor immunogenic CMV proteins pp65, pp50, and IE1 were isolated
